Patents by Inventor Jeffrey Charles Way
Jeffrey Charles Way has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795212Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.Type: GrantFiled: November 10, 2020Date of Patent: October 24, 2023Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. Ingber, Michael Super, Jeffrey Charles Way, Mark J. Cartwright, Julia B. Berthet, Dinah R. Super, Martin Rottman, Alexander L. Watters
-
Publication number: 20230242895Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: ApplicationFiled: February 10, 2023Publication date: August 3, 2023Inventors: Edwin L. MADISON, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
-
Patent number: 11613744Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: GrantFiled: January 3, 2020Date of Patent: March 28, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
-
Publication number: 20230038638Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.Type: ApplicationFiled: June 14, 2021Publication date: February 9, 2023Inventors: Grant E. BLOUSE, Brajesh KUMAR, Tom KNUDSEN, Jan Kristian JENSEN, Emil OLDENBURG, Christine René SCHAR, Matthew John TRAYLOR, Eric Steven FURFINE, Jeffrey Charles WAY, Agnieszka JENDROSZEK, Arzu SANDIKCI, Jim MCGUIRE, Shyam Rajan IYER, Natacha LE MOAN
-
Publication number: 20220267794Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.Type: ApplicationFiled: March 27, 2020Publication date: August 25, 2022Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
-
Publication number: 20220098261Abstract: The technology described herein is directed to engineered polypeptides comprising an anti-GYPA antibody reagent and an EPO polypeptide. Further provided herein are methods of treating anemia by administering said polypeptides.Type: ApplicationFiled: December 19, 2019Publication date: March 31, 2022Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Jungmin LEE, Jeffrey Charles WAY
-
Publication number: 20220056089Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: ApplicationFiled: November 9, 2021Publication date: February 24, 2022Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael SUPER, Jeffrey Charles WAY, Donald E. INGBER
-
Patent number: 11203623Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: GrantFiled: June 4, 2020Date of Patent: December 21, 2021Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
-
Publication number: 20210222143Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: ApplicationFiled: January 3, 2020Publication date: July 22, 2021Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
-
Patent number: 11059873Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: GrantFiled: December 4, 2019Date of Patent: July 13, 2021Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
-
Patent number: 11059874Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: GrantFiled: June 4, 2020Date of Patent: July 13, 2021Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
-
Publication number: 20210155677Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.Type: ApplicationFiled: November 10, 2020Publication date: May 27, 2021Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. INGBER, Michael SUPER, Jeffrey Charles WAY, Mark J. CARTWRIGHT, Julia B. BERTHET, Dinah R. SUPER, Martin ROTTMAN, Alexander L. WATTERS
-
Patent number: 11014973Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer.Type: GrantFiled: November 26, 2019Date of Patent: May 25, 2021Assignee: President and Fellows of Harvard CollegeInventors: Jeffrey Charles Way, Avram Lev Robinson-Mosher
-
Patent number: 10907221Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.Type: GrantFiled: June 5, 2018Date of Patent: February 2, 2021Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Jonathan Kotula, Scott Jordan Kerns, Jeffrey Charles Way, Pamela A. Silver, Lev Shaket
-
Patent number: 10865235Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.Type: GrantFiled: November 14, 2019Date of Patent: December 15, 2020Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. Ingber, Michael Super, Jeffrey Charles Way, Mark J. Cartwright, Julia B. Berthet, Dinah R. Super, Martin Rottman, Alexander L. Watters
-
Publication number: 20200299345Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: ApplicationFiled: June 4, 2020Publication date: September 24, 2020Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael SUPER, Jeffrey Charles WAY, Donald E. INGBER
-
Publication number: 20200291083Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: ApplicationFiled: June 4, 2020Publication date: September 17, 2020Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael SUPER, Jeffrey Charles WAY, Donald E. INGBER
-
Publication number: 20200291085Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g.Type: ApplicationFiled: November 26, 2019Publication date: September 17, 2020Applicants: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Jeffrey Charles Way, Avram Lev Robinson-Mosher, Thomas M. Roberts, Jean Zhao
-
Publication number: 20200239552Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.Type: ApplicationFiled: November 14, 2019Publication date: July 30, 2020Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. INGBER, Michael SUPER, Jeffrey Charles WAY, Mark J. CARTWRIGHT, Julia B. BERTHET, Dinah R. SUPER, Martin ROTTMAN, Alexander L. WATTERS
-
Publication number: 20200208133Abstract: Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.Type: ApplicationFiled: January 3, 2020Publication date: July 2, 2020Inventors: Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way